Related Experiment Videos
99Tcm-dextran: a potential inflammation-seeking radiopharmaceutical
A Bhatnagar1, A K Singh, T Singh
1Department of Nuclear Medicine, Institute of Nuclear Medicine and Allied Sciences, Lucknow Marg, Delhi, India.
Nuclear Medicine Communications
|December 1, 1995
Summary
Technetium-99m-labeled dextran (99Tcm-dextran) shows promise as an inflammation-imaging agent. This radiotracer selectively concentrates in inflamed tissues, aiding in the detection of inflammatory lesions.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical science
- Inflammation imaging
Background:
- Inflammation imaging is crucial for diagnosing and monitoring various medical conditions.
- Current imaging agents may have limitations in specificity or sensitivity.
Purpose of the Study:
- To evaluate the efficacy of 99Tcm-dextran as a novel radiotracer for imaging inflammation.
- To determine the optimal imaging time and assess the tracer's uptake in an in vivo inflammation model.
Main Methods:
- An inflammation model was induced in rabbits via intramuscular injection of Freund's complete adjuvant.
- Serial scintigraphic imaging was performed using 99Tcm-dextran over two weeks.
- Quantitative analysis included target-to-nontarget ratios and assessment of lesion visualization.
Main Results:
- 99Tcm-dextran selectively concentrated in inflammatory lesions, with a mean target-to-nontarget ratio of 3.01 from day 4 onwards.
- The scintigraphic abnormality area exceeded the physical lesion size, indicating sensitive detection.
- Optimal imaging was achieved 2-4 hours post-administration, with tracer uptake potentially linked to increased capillary permeability.
Conclusions:
- 99Tcm-dextran demonstrates potential as an inflammation-seeking radiotracer.
- Further evaluation is warranted to establish its clinical utility in diagnosing inflammatory conditions.